Jazz Pharmaceuticals Expands Pipeline with $1.32 Billion Acquisition of Actio Biosciences
Jazz Pharmaceuticals announces $1.32 billion acquisition of Actio Biosciences, enhancing its rare disease pipeline.
AbCellera Biologics Stock Soars on Positive Phase 2 Trial Results
AbCellera's shares surged 30.3% after positive Phase 2 trial results for its innovative antibody, ABCL635.
Amneal Pharmaceuticals' Strategic Move: Acquisition of Kashiv BioSciences
Amneal's acquisition of Kashiv BioSciences positions it as a leader in the biosimilars market, indicating potential revenue growth.
Jazz Pharmaceuticals' $1.32B Acquisition: What Investors Need to Know
Jazz Pharmaceuticals is set to acquire Actio Biosciences for $1.32 billion, a move that could reshape its market position.
Potential New Revenue Stream: AbbVie’s BOTOX Cosmetic Application Progress and Market Implications
Exploring the implications of FDA's acceptance of BOTOX for masseter muscle prominence on AbbVie's financial outlook.
Spectral Medical (TSX: EDT) Announces Q2 2026 Results and FDA Progress: A Game Changer for Investors
Spectral Medical's Q2 2026 results and FDA advancements could redefine shareholder value and commercialization prospects.
iRhythm's Strong Q2 Earnings and Vital Connect Acquisition: A Sign of Growth
iRhythm's Q2 earnings beat and acquisition of Vital Connect signal promising growth in wearable health tech.
Eli Lilly's Next-Gen Weight-Loss Drug Filing: A Game Changer for Investors
Eli Lilly's FDA filing for a new weight-loss drug could reshape the market landscape and challenge competitors like Novo Nordisk.
NRx Pharmaceuticals Moves Closer to Launching Preservative-Free Ketamine
NRx Pharmaceuticals' ANDA for preservative-free ketamine passes FDA first-cycle review, signaling significant market potential.
Moderna's mRNA Flu Vaccine Approval: A Milestone with Market Implications
Moderna's recent FDA approval for its mRNA flu vaccine marks a significant step, yet market sentiment remains cautious.
Harrow's Strategic Acquisition of TYRVAYA: A Game-Changer for Ophthalmic Treatments
Harrow's acquisition of TYRVAYA positions it as a key player in ophthalmic treatments, offering potential revenue growth.
Tarsus Pharmaceuticals Expands Eye Care Pipeline with Alkeus Acquisition
Tarsus Pharmaceuticals strengthens its eye care portfolio by acquiring Alkeus Pharmaceuticals, focusing on gildeuretinol, a potential Starga…